Q-omics provides the consensus-scored RRP12 profile across patient tissues and cancer cell-line models. RRP12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RRP12 is differentially expressed in 17, with the highest sampling consensus in STAD. Additionally, RRP12 protein abundance shows 36,534 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, STAD, and GBM as cancer lineages where RRP12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RRP12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RRP12 survival associations across molecular data types. RRP12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RRP12 RNA expression–survival associations across cancer types. High RRP12 expression shows unfavorable associations in ACC, LIHC, KIRC, BLCA, MESO and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RRP12 RNA expression.
This table summarizes RRP12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RRP12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RRP12 shows higher tumor expression in STAD, COAD, KIRP, LIHC, LUAD and KIRC. The STAD box plot shows higher RRP12 RNA expression in tumor versus normal tissue (log2 FC = +1.653, t-test p < 0.001).
This table shows molecular features associated with RRP12 in patient tissues and cancer cell lines. In patient samples, RRP12 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RRP12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
